Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2016

01-12-2016 | DDS Mentored Reviews

FXR Agonists: From Bench to Bedside, a Guide for Clinicians

Authors: Ahmad Samer Alawad, Cynthia Levy

Published in: Digestive Diseases and Sciences | Issue 12/2016

Login to get access

Excerpt

Farnesoid X receptors (FXRs) belong to a superfamily of receptors known as the nuclear hormone receptors [1]. Nuclear hormone receptors are ligand-activated transcription factors that regulate key functions including cell differentiation, several metabolic pathways such as insulin signaling, cholesterol homeostasis, and bile acid metabolism [2]. These receptors have highly conserved DNA- and ligand-binding domains, and depending on their DNA-binding properties, they are further subclassified into different subcategory receptors including farnesoid X receptors (FXRs). These receptors are highly expressed in tissues that are involved in bile acid (BA) metabolism such as liver and intestines, and they are also present in kidney and to a lower extent in adipose tissue [3]. They are responsible for modulating BA homeostasis by regulating genes involved in BA synthesis, secretion, conjugation, transportation, absorption, and detoxification [4]. …
Literature
1.
go back to reference Blumberg B, Evans RM. Orphan nuclear receptors–new ligands and new possibilities. Genes Dev. 1998;12:3149–3155.CrossRefPubMed Blumberg B, Evans RM. Orphan nuclear receptors–new ligands and new possibilities. Genes Dev. 1998;12:3149–3155.CrossRefPubMed
2.
go back to reference Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744.CrossRefPubMed Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744.CrossRefPubMed
3.
go back to reference Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–191.CrossRefPubMed Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–191.CrossRefPubMed
4.
go back to reference Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–225.CrossRefPubMed Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–225.CrossRefPubMed
5.
go back to reference Kok T, Hulzebos CV, Wolters H, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem. 2003;278:41930–41937.CrossRefPubMed Kok T, Hulzebos CV, Wolters H, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem. 2003;278:41930–41937.CrossRefPubMed
6.
go back to reference Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.CrossRefPubMed Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.CrossRefPubMed
7.
go back to reference Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci. 2007;28:236–243.CrossRefPubMed Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci. 2007;28:236–243.CrossRefPubMed
8.
go back to reference Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581–1591.CrossRefPubMedPubMedCentral Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581–1591.CrossRefPubMedPubMedCentral
9.
go back to reference Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48:1632–1643.CrossRefPubMedPubMedCentral Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48:1632–1643.CrossRefPubMedPubMedCentral
10.
go back to reference Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53:1023–1034.CrossRefPubMed Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53:1023–1034.CrossRefPubMed
11.
go back to reference Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988–997.CrossRefPubMed Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988–997.CrossRefPubMed
12.
go back to reference Pellicciari R, Costantino G, Camaioni E, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004;47:4559–4569.CrossRefPubMed Pellicciari R, Costantino G, Camaioni E, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004;47:4559–4569.CrossRefPubMed
13.
go back to reference Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771–784.CrossRefPubMedPubMedCentral Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771–784.CrossRefPubMedPubMedCentral
14.
go back to reference Vignozzi L, Morelli A, Filippi S, et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med. 2011;8:57–77.CrossRefPubMed Vignozzi L, Morelli A, Filippi S, et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med. 2011;8:57–77.CrossRefPubMed
15.
go back to reference Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103:1006–1011.CrossRefPubMedPubMedCentral Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103:1006–1011.CrossRefPubMedPubMedCentral
16.
go back to reference Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–11049.CrossRefPubMed Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–11049.CrossRefPubMed
17.
go back to reference Ma Y, Huang Y, Yan L, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res. 2013;30:1447–1457.CrossRefPubMedPubMedCentral Ma Y, Huang Y, Yan L, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res. 2013;30:1447–1457.CrossRefPubMedPubMedCentral
18.
go back to reference Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621–1624.CrossRefPubMedPubMedCentral Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621–1624.CrossRefPubMedPubMedCentral
21.
go back to reference Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497–1512.CrossRefPubMed Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497–1512.CrossRefPubMed
22.
go back to reference Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28:940–946.CrossRefPubMed Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28:940–946.CrossRefPubMed
23.
go back to reference Degirolamo C, Modica S, Vacca M, et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology. 2015;61:161–170.CrossRefPubMed Degirolamo C, Modica S, Vacca M, et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology. 2015;61:161–170.CrossRefPubMed
24.
go back to reference Guo F, Xu Z, Zhang Y, et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget. 2015;6:34606–34616.PubMedPubMedCentral Guo F, Xu Z, Zhang Y, et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget. 2015;6:34606–34616.PubMedPubMedCentral
25.
go back to reference He J, Zhao K, Zheng L, et al. Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol Cancer. 2015;14:163.CrossRefPubMedPubMedCentral He J, Zhao K, Zheng L, et al. Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol Cancer. 2015;14:163.CrossRefPubMedPubMedCentral
26.
go back to reference Flatt B, Martin R, Wang TL, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009;52:904–907.CrossRefPubMed Flatt B, Martin R, Wang TL, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009;52:904–907.CrossRefPubMed
27.
go back to reference Mencarelli A, Renga B, Distrutti E, et al. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009;296:H272–H281.CrossRefPubMed Mencarelli A, Renga B, Distrutti E, et al. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009;296:H272–H281.CrossRefPubMed
28.
go back to reference Wu W, Zhu B, Peng X, et al. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2014;443:68–73.CrossRefPubMed Wu W, Zhu B, Peng X, et al. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2014;443:68–73.CrossRefPubMed
29.
go back to reference Livero FA, Stolf AM, Dreifuss AA, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact. 2014;217:19–27.CrossRefPubMed Livero FA, Stolf AM, Dreifuss AA, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact. 2014;217:19–27.CrossRefPubMed
30.
go back to reference Wu W, Liu X, Peng X, et al. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun. 2014;448:50–55.CrossRefPubMed Wu W, Liu X, Peng X, et al. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun. 2014;448:50–55.CrossRefPubMed
31.
go back to reference Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380–388.CrossRefPubMed Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380–388.CrossRefPubMed
32.
go back to reference Yao J, et al. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol. 2014;20:14430–14441.CrossRefPubMedPubMedCentral Yao J, et al. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol. 2014;20:14430–14441.CrossRefPubMedPubMedCentral
33.
go back to reference Pellicciari R, Zhou CS, Ma X, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.CrossRefPubMed Pellicciari R, Zhou CS, Ma X, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.CrossRefPubMed
34.
go back to reference Wu WB, Xu YY, Cheng WW, et al. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta—a study on maternal cholestasis model. Placenta. 2015;36:545–551.CrossRefPubMed Wu WB, Xu YY, Cheng WW, et al. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta—a study on maternal cholestasis model. Placenta. 2015;36:545–551.CrossRefPubMed
35.
go back to reference Lian F, Wang Y, Xiao Y, et al. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis. Mol Med Rep. 2015;12:5821–5827.PubMedPubMedCentral Lian F, Wang Y, Xiao Y, et al. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis. Mol Med Rep. 2015;12:5821–5827.PubMedPubMedCentral
36.
go back to reference Mencarelli A, Renga B, Migliorati M, et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol. 2009;183:6657–6666.CrossRefPubMed Mencarelli A, Renga B, Migliorati M, et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol. 2009;183:6657–6666.CrossRefPubMed
37.
go back to reference Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286–2298.CrossRefPubMed Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286–2298.CrossRefPubMed
38.
go back to reference Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10:1352–1358.CrossRefPubMed Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10:1352–1358.CrossRefPubMed
39.
go back to reference Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.CrossRefPubMed Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.CrossRefPubMed
40.
go back to reference Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850.CrossRefPubMed Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850.CrossRefPubMed
41.
go back to reference Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-82.e1.CrossRefPubMed Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-82.e1.CrossRefPubMed
42.
go back to reference Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.CrossRefPubMed Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.CrossRefPubMed
43.
go back to reference Hameed B, Terrault N, Gill R, et al. Separate and combined effects of obeticholic acid and weight loss in nonalcoholic steatohepatitis (NASH). J Hepatol. 2015;62:S271.CrossRef Hameed B, Terrault N, Gill R, et al. Separate and combined effects of obeticholic acid and weight loss in nonalcoholic steatohepatitis (NASH). J Hepatol. 2015;62:S271.CrossRef
44.
go back to reference Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751-61.e8.CrossRefPubMed Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751-61.e8.CrossRefPubMed
45.
go back to reference Kowdley KV, Luketic V, Chapman R. An International Study Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid as Monotherapy in PBC. Vol. 54. Berlin: European Association for the Study of the Liver; 2011. Kowdley KV, Luketic V, Chapman R. An International Study Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid as Monotherapy in PBC. Vol. 54. Berlin: European Association for the Study of the Liver; 2011.
46.
go back to reference Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.CrossRefPubMed Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.CrossRefPubMed
47.
go back to reference Cho SW, An JH, Park H, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013;28:2109–2121.CrossRefPubMed Cho SW, An JH, Park H, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013;28:2109–2121.CrossRefPubMed
48.
go back to reference Pares A, Pencek R, Peters Y, et al. FXR agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis. J Hepatol. 2015;62:S786.CrossRef Pares A, Pencek R, Peters Y, et al. FXR agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis. J Hepatol. 2015;62:S786.CrossRef
49.
go back to reference Mookerjee R, Rosselli M, Pieri G, et al. Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: a proof of concept phase 2 a study. J Hepatol. 2014;60:S7-S8.CrossRef Mookerjee R, Rosselli M, Pieri G, et al. Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: a proof of concept phase 2 a study. J Hepatol. 2014;60:S7-S8.CrossRef
Metadata
Title
FXR Agonists: From Bench to Bedside, a Guide for Clinicians
Authors
Ahmad Samer Alawad
Cynthia Levy
Publication date
01-12-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4334-8

Other articles of this Issue 12/2016

Digestive Diseases and Sciences 12/2016 Go to the issue

PROFILES AND PERSPECTIVES

Profiles: Raymond S. Koff, MD